3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Ovarian Neoplasms
7
Uterine Cervical Neoplasms
2
Rectal Neoplasms
2
Endometrial Neoplasms
2
Uveal Melanoma
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Pleural Effusion, Malignant
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Leiomyosarcoma
1
Gliosarcoma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Ipilimumab
17
Nivolumab
15
incomplete Freund's adjuvant
8
Cyclophosphamide
7
CTLA-4 Antigen
7
pembrolizumab
6
Ranibizumab
6
sargramostim
5
Radiosurgery
5
Blood Specimen Collection
5
tebentafusp
4
Temozolomide
4
Surveys and Questionnaires
4
Magnetic Resonance Spectroscopy
4
MART-1 Antigen
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
Biopsy
4
Bevacizumab
4
fludarabine phosphate
3
fludarabine
3
aflibercept
3
Thalidomide
3
Sunitinib
3
Specimen Handling
3
MAGEA3 protein, human
3
Interleukin-2
3
130-nm albumin-bound paclitaxel
3
relatlimab
2
olaparib
2
montanide ISA 51
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Uveal Melanoma
×
cediranib
×
Clear all
NCT04184518
2020-06-02
CEDUVEAL-M
Grupo Español Multidisciplinar de Melanoma
Phase 2
Withdrawn